Immunotherapy Combined With Standard Therapies in Head and Neck Squamous Cell Carcinoma – A Meta-analysis

EDEN, DAISY; GHOSE, ARUNI; MOSCHETTA, MICHELE; PÉREZ-FIDALGO, JOSÉ ALEJANDRO; RASSY, ELIE; BOUSSIOS, STERGIOS

doi:10.21873/anticanres.16880

Cited by 5 publications

(1 citation statement)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This pathway inhibits T cell glycolysis and releases IFNy and Th1 cytokines [223] . Thus, immunotherapy with anti-PD-L1 drugs makes a good response in obese patients [224] . Identifying the molecular mechanisms that enable microbes to communicate with cells that modulate the immune system is imperative.…”

Section: The Effect Of Exposure On Immunity and Immune Checkpoint Inh...mentioning

confidence: 99%

The role of PD-1/PD-L1 signaling pathway in cancer pathogenesis and treatment: a systematic review

Sabaghian,

Shamsabadi,

Momeni

et al. 2024

J Cancer Metastasis Treat

View full text Add to dashboard Cite

Aim: Cancer as a complex disease poses significant challenges for both diagnosis and treatment. Researchers have been exploring various avenues to find effective therapeutic strategies, with a particular emphasis on cellular signaling pathways and immunotherapy. One such pathway that has recently been suggested is the PD-1/PD-L1 pathway, which is an immune checkpoint signaling system that plays an important role in regulating the immune system and maintaining tissue homeostasis. Cancer cells exploit this pathway by producing PD-L1, which attaches to PD-1 on T cells, thus inhibiting immune responses and enabling the cancer cells to escape detection by the immune system. This study aimed to evaluate the role of the PD-1/PD-L1 pathway in cancer pathogenesis and treatment. Method: This study was performed based on the principles of Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA). All in vitro , in vivo , and clinical studies that were published in English have been considered during a thorough search of the Scopus, Web of Science, and PubMed databases without date restriction until March 2024. Results: According to the studies reviewed, the PD-1/PD-L1 signaling axis suggests promising therapeutic effects on various types of cancers such as non-small cell lung cancer, melanoma, breast cancer, hepatocellular carcinoma, squamous cell carcinoma, and colorectal cancer, among others. Additionally, research suggests that immune checkpoint inhibitors that block PD1/PD-L1, such as pembrolizumab, atezolizumab, nivolumab, durvalumab, cemiplimab, avelumab, etc. , can effectively prevent tumor cells from escaping the immune system. Moreover, there might be a possible interaction between microbiome, obesity, etc. on immune mechanisms and on the immune checkpoint inhibitors (ICIs). Conclusion: Although we have gained considerable knowledge about ICIs, we are still facing challenges in effectively prescribing the appropriate ICIs for individual patients. This is largely due to the complex interactions between different intracellular pathways, which need to be thoroughly studied. To resolve this issue, it is necessary to conduct more reliable clinical trials that can produce a scientific consensus.

show abstract

Section: The Effect Of Exposure On Immunity and Immune Checkpoint Inh...mentioning

confidence: 99%